[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:programmed-cell-death-protein-1":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Programmed Cell Death Protein 1",17,15,[8,16,23,30,36,42,48,55,61,67,73,79,85,91,97,104,111],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07252739","KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J\u002FKEYMAKER-U01J)",[12],"Phase 2","RECRUITING","2026-08-26T02:16:09.452956Z","2026-07-30T01:46:14.436674Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06585410","Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma",[20],"Phase 3","2026-08-26T02:16:21.385056Z","2026-07-05T05:32:16.760741Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT07355205","First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer",[27],"Phase 1\u002FPhase 2","2026-08-26T02:17:03.534765Z","2026-07-05T05:32:16.677180Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT05317000","5-Azacytidine and\u002For Nivolumab in Resectable HPV-Associated HNSCC",[12],"2026-08-26T02:15:18.897219Z","2026-06-17T02:29:29.995073Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06841354","A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011\u002FTroFuse-011)",[20],"2026-08-26T02:18:59.761994Z","2026-06-16T05:54:07.924230Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT05633654","Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05\u002FAFT-65 OptimICE-RD\u002FGBG 119\u002FNSABP B-63)",[20],"2026-08-26T02:15:37.042762Z","2026-06-16T05:54:07.910708Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":53,"content_modified":54},"NCT07619599","A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab",[52],"Phase 1","2026-08-26T02:19:09.651016Z","2026-06-04T01:30:07.904532Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT05855200","Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR\u002FMSI-H Resectable Colon Cancer",[20],"2026-08-26T02:18:13.438956Z","2026-05-05T02:43:27.110176Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06699212","A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases",[20],"2026-08-26T02:19:06.150683Z","2026-05-05T02:43:27.037240Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT04895709","A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors",[27],"2026-08-26T02:19:00.742020Z","2026-06-16T05:54:07.907527Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06425926","Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors",[27],"2026-08-26T02:18:09.641312Z","2026-05-05T02:43:27.481608Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT07646847","A Study of a Side Effects and Resource Navigation Program for People With Cancer",[],"2026-08-26T02:18:45.196599Z","2026-07-30T01:46:14.435535Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT06741644","A Phase I\u002FII Study of CS2009 in Participants With Advanced Solid Tumors",[27],"2026-08-26T02:17:28.381459Z","2026-07-19T19:36:05.136448Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT07058012","A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)",[12],"2026-08-26T02:19:07.104270Z","2026-07-05T05:32:16.733669Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":102,"content_modified":103},"NCT07210632","Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)",[101],"Early Phase 1","2026-08-26T02:18:30.351130Z","2026-07-05T05:32:16.660346Z",{"nct_id":105,"title":106,"phases":107,"status":108,"updated_at":109,"content_modified":110},"NCT07388550","Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)",[52],"NOT_YET_RECRUITING","2026-08-26T02:18:41.390601Z","2026-05-05T02:43:29.532550Z",{"nct_id":112,"title":113,"phases":114,"status":108,"updated_at":115,"content_modified":116},"NCT07718854","Sacituzumab Tirumotecan +\u002F- Pembrolizumab in I\u002FO Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer",[12],"2026-08-26T02:17:51.502023Z","2026-07-24T01:27:14.918587Z"]